Toronto-based startup Science&Humans has secured $10 million CAD in Series A funding to expand its telemedicine platform focused on hormone health. This marks the company’s first external funding, comprising $7 million in equity and $3 million in venture debt. The funds are expected to help the company scale beyond its current 60,000 patients.
### Science&Humans’ Innovative Approach
Founded seven years ago, Science&Humans offers digital access to personalized hormone health treatments for issues like low testosterone, menopause, and weight management. The platform connects patients with specialists for continuous care, combining consultations with prescription drugs when necessary. CEO Aftab Pashaw emphasizes the company’s focus on addressing the root causes of hormone imbalances, rather than solely dispensing medications. The startup partners with major health insurers and large companies, differentiating itself from other telehealth providers by focusing on a business-to-business model.
### Context and Competition
Interest in hormone health is growing, with Science&Humans joining a wave of healthtech companies addressing this need. Competitors like Toronto-based Phoenix and Felix Health have also recently secured significant funding. Montréal’s Eli Health, which has developed hormone monitoring technology, has followed a similar trajectory. Science&Humans has facilitated nearly one million patient consultations, with more than 80% of patients reporting symptom improvement within three to six months.
### Industry Implications
The rise of digital health platforms is bringing hormone health into the mainstream. Science&Humans’ approach, which includes thorough patient intake processes and regular consultations, aims to ensure patient safety and effective treatment outcomes. The company plans to use its new funding to expand its B2B operations and enhance its technological capabilities, including developing a comprehensive “hormone operating system” that integrates pharmacies and labs.
As Science&Humans continues to grow, its focus on scalable, high-quality care through employers and insurers positions it to play a significant role in the evolving telemedicine landscape. The startup’s next steps involve nationwide scaling and further development of its tech and AI capabilities, promising to broaden access to hormone health solutions across Canada.
